Racial differences in postpandemic trends in prostate-specific antigen screening.

IF 3.4 Q2 ONCOLOGY JNCI Cancer Spectrum Pub Date : 2024-02-29 DOI:10.1093/jncics/pkae016
Zhiyu Qian, Jameshisa Alexander, Danesha Daniels, Firas Abdollah, Alexander P Cole, Hari S Iyer, Quoc-Dien Trinh
{"title":"Racial differences in postpandemic trends in prostate-specific antigen screening.","authors":"Zhiyu Qian, Jameshisa Alexander, Danesha Daniels, Firas Abdollah, Alexander P Cole, Hari S Iyer, Quoc-Dien Trinh","doi":"10.1093/jncics/pkae016","DOIUrl":null,"url":null,"abstract":"<p><p>Our study investigates the trends in prostate cancer screening amid the COVID-19 pandemic, particularly focusing on racial disparities between Black and White men. Utilizing data from the Behavioral Risk Factor Surveillance System from 2018, 2020, and 2022, we analyzed prostate-specific antigen screening rates in men aged 45-75 years. Our findings reveal initial declines in screening rates for both groups during the pandemic, with subsequent recovery; however, the pace of rebound differed statistically significantly between races. Whereas White men showed a notable increase in screening rates postpandemic, Black men's rates recovered more slowly. This disparity underscores the impact of socioeconomic factors, health-care access, and possibly systemic biases affecting health-care delivery. Our study highlights the need for targeted interventions to address these inequalities and ensure equitable access to prostate cancer preventive care in the aftermath of COVID-19.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":"8 2","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10977270/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Cancer Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncics/pkae016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Our study investigates the trends in prostate cancer screening amid the COVID-19 pandemic, particularly focusing on racial disparities between Black and White men. Utilizing data from the Behavioral Risk Factor Surveillance System from 2018, 2020, and 2022, we analyzed prostate-specific antigen screening rates in men aged 45-75 years. Our findings reveal initial declines in screening rates for both groups during the pandemic, with subsequent recovery; however, the pace of rebound differed statistically significantly between races. Whereas White men showed a notable increase in screening rates postpandemic, Black men's rates recovered more slowly. This disparity underscores the impact of socioeconomic factors, health-care access, and possibly systemic biases affecting health-care delivery. Our study highlights the need for targeted interventions to address these inequalities and ensure equitable access to prostate cancer preventive care in the aftermath of COVID-19.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
前列腺特异性抗原筛查流行后趋势的种族差异。
我们的研究调查了 COVID-19 流行期间前列腺癌筛查的趋势,尤其关注黑人和白人男性之间的种族差异。利用行为风险因素监测系统 2018 年、2020 年和 2022 年的数据,我们分析了 45-75 岁男性的前列腺特异性抗原筛查率。我们的研究结果表明,在大流行期间,两个群体的筛查率最初都有所下降,随后有所恢复;然而,不同种族的反弹速度在统计学上存在显著差异。白人男性的筛查率在大流行后明显上升,而黑人男性的筛查率恢复得更慢。这种差异凸显了社会经济因素、医疗服务的可及性以及可能影响医疗服务的系统性偏见的影响。我们的研究突出表明,有必要采取有针对性的干预措施来解决这些不平等现象,并确保在 COVID-19 之后能够公平地获得前列腺癌预防保健服务。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JNCI Cancer Spectrum
JNCI Cancer Spectrum Medicine-Oncology
CiteScore
7.70
自引率
0.00%
发文量
80
审稿时长
18 weeks
期刊最新文献
Trends in Enforcement of National Comprehensive Cancer Network Financial Conflict of Interest Policy. Cancer Clinical Trial Participation: A Qualitative Study of Black/African American Communities' and Patient/Survivors' Recommendations. Social determinants of health and variability in treatment for patients with early-stage Non-Small Cell Lung Cancer. Inequities in palliative care delivery to patients with HIV and Stage IV cancers in the US (2004-2020). Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1